Great West Life Assurance Co. Can Has $245,000 Holdings in Penumbra, Inc. (PEN)
Great West Life Assurance Co. Can continued to hold its position in shares of Penumbra, Inc. (NYSE:PEN) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,800 shares of the company’s stock at the end of the second quarter. Great West Life Assurance Co. Can’s holdings in Penumbra were worth $245,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Ameritas Investment Partners Inc. purchased a new position in shares of Penumbra in the 1st quarter valued at $194,000. FNY Partners Fund LP purchased a new position in shares of Penumbra in the 1st quarter valued at $223,000. Amalgamated Bank purchased a new position in shares of Penumbra in the 1st quarter valued at $274,000. Suntrust Banks Inc. increased its holdings in shares of Penumbra by 1.8% in the 1st quarter. Suntrust Banks Inc. now owns 3,922 shares of the company’s stock valued at $327,000 after acquiring an additional 71 shares during the period. Finally, Clinton Group Inc. purchased a new position in shares of Penumbra in the 1st quarter valued at $463,000. Institutional investors and hedge funds own 70.93% of the company’s stock.
A number of research analysts have recently issued reports on the company. BidaskClub upgraded Penumbra from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. Zacks Investment Research downgraded Penumbra from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. Canaccord Genuity reiterated a “buy” rating and issued a $100.00 price target (up from $94.00) on shares of Penumbra in a report on Wednesday, August 9th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $96.00 price target on shares of Penumbra in a report on Friday, June 16th.
Penumbra, Inc. (PEN) opened at 88.15 on Thursday. Penumbra, Inc. has a one year low of $56.05 and a one year high of $91.00. The stock has a 50 day moving average price of $85.10 and a 200-day moving average price of $84.19. The stock has a market capitalization of $2.98 billion, a P/E ratio of 595.61 and a beta of 0.09.
Penumbra (NYSE:PEN) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). Penumbra had a negative return on equity of 2.58% and a negative net margin of 2.78%. The business had revenue of $80.60 million for the quarter, compared to analyst estimates of $77.16 million. During the same quarter in the prior year, the company earned $0.01 earnings per share. The company’s revenue was up 23.8% on a year-over-year basis. Analysts anticipate that Penumbra, Inc. will post ($0.21) earnings per share for the current year.
In other news, insider Daniel Donen Davis sold 32,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $79.42, for a total transaction of $2,541,440.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Robert D. Evans sold 10,000 shares of the company’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $85.15, for a total value of $851,500.00. Following the sale, the executive vice president now directly owns 11,704 shares in the company, valued at approximately $996,595.60. The disclosure for this sale can be found here. Insiders have sold 46,845 shares of company stock worth $3,794,570 in the last ninety days. Corporate insiders own 22.00% of the company’s stock.
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.